Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company GlaxoSmithKline plc
DescriptionRecombinant chimpanzee adenovirus type 3 (ChAd3) vector vaccine expressing the wild-type Ebola glycoproteins from the Zaire and Sudan Ebola strains
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase I
Standard IndicationEbola
Indication DetailsPrevent Ebola virus infection
Regulatory Designation
PartnerNational Institutes of Health

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today